ClinicalTrials.gg
CompletedNCT00907738Updated May 21, 2015Results posted

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

A Phase 2 interventional study of vorinostat in Advanced Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug
  • Patient did not withdraw from the base protocol
  • Patient agrees to practice effective during the study

Exclusion criteria

Exclusion Criteria:

  • Patient is receiving other standard and/or anticancer therapy
  • Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Vorinostat

    Drug: vorinostat

Interventions

  • All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.

    Also known as: MK-0683

06

What researchers measure

Primary outcomes

  1. Percent of Participants With a Serious Drug-related Adverse Event (AE)

    A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose. A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug.

    Time frame: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)

07

Results

Posted Jul 14, 2011
Limitations and caveats
Non-serious adverse events were only collected if they caused drug interruption, discontinuation, or dose reduction.

Participant flow

Participant flow — Overall Study
MilestoneBase Protocol 001Base Protocol 006Base Protocol 008Base Protocol 012Base Protocol 013
Started131742
Completed00000
Not completed131742
Withdrew: Adverse event20100
Withdrew: Not specified or withdrew consent30000
Withdrew: Disease progression81642

Outcome measures

PrimaryPercent of Participants With a Serious Drug-related Adverse Event (AE)

A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose. A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug.

Time frame:
From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)
Reported as:
Number · percent of participants
Percent of Participants With a Serious Drug-related Adverse Event (AE)
percent of participantsBase Protocol 001Base Protocol 006Base Protocol 008Base Protocol 012Base Protocol 013
Percent of Participants With a Serious Drug-related Adverse Event (AE)7.70000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Protocol 001 (Vorinostat 400 mg Once Daily [QD])—4/13 (30.8%)6/13 (46.2%)
Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID])—1/1 (100%)0/1 (0%)
Base Protocol 008 (Vorinostat 400 mg Once Daily [QD])—1/7 (14.3%)2/7 (28.6%)
Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21)—0/1 (0%)0/1 (0%)
Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7)—1/1 (100%)1/1 (100%)
Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21)—0/1 (0%)0/1 (0%)
Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21)—0/1 (0%)0/1 (0%)
Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21)—0/1 (0%)1/1 (100%)
Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7)—0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventBase Protocol 001 (Vorinostat 400 mg Once Daily [QD])Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID])Base Protocol 008 (Vorinostat 400 mg Once Daily [QD])Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21)Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7)Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21)Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21)Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21)Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7)
Chest painGeneral disorders0/130/10/70/11/10/10/10/10/1
CholangitisHepatobiliary disorders0/131/10/70/10/10/10/10/10/1
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/11/70/10/10/10/10/10/1
Tongue neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/11/70/10/10/10/10/10/1
CholecystitisHepatobiliary disorders1/130/10/70/10/10/10/10/10/1
PneumoniaInfections and infestations1/130/10/70/10/10/10/10/10/1
Blood creatine phosphokinase increasedInvestigations1/130/10/70/10/10/10/10/10/1
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/130/10/70/10/10/10/10/10/1
RashSkin and subcutaneous tissue disorders1/130/10/70/10/10/10/10/10/1
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBase Protocol 001 (Vorinostat 400 mg Once Daily [QD])Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID])Base Protocol 008 (Vorinostat 400 mg Once Daily [QD])Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21)Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7)Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21)Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21)Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21)Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7)
ThrombocytopeniaBlood and lymphatic system disorders3/130/10/70/10/10/10/11/10/1
NauseaGastrointestinal disorders1/130/10/70/10/10/10/10/11/1
FatigueGeneral disorders0/130/10/70/11/10/10/10/10/1
Lobar pneumoniaInfections and infestations0/130/10/70/10/10/10/11/10/1
DiarrhoeaGastrointestinal disorders2/130/10/70/10/10/10/10/10/1
Abdominal pain lowerGastrointestinal disorders0/130/11/70/10/10/10/10/10/1
AnorexiaMetabolism and nutrition disorders0/130/11/70/10/10/10/10/10/1
ConstipationGastrointestinal disorders1/130/10/70/10/10/10/10/10/1
Blood creatine phosphokinase increasedInvestigations1/130/10/70/10/10/10/10/10/1
Blood lactate dehydrogenase increasedInvestigations1/130/10/70/10/10/10/10/10/1

Baseline characteristics

Age, Customized
Age, Customized(Participants)Base Protocol 001Base Protocol 006Base Protocol 008Base Protocol 012Base Protocol 013Total
Number13174227
Sex: Female, Male
Sex: Female, Male(Participants)Base Protocol 001Base Protocol 006Base Protocol 008Base Protocol 012Base Protocol 013Total
Female8041215
Male5133012
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. doi: 10.3816/CLM.2009.n.082. PubMed 19951879 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2009
First posted
May 25, 2009
Start
Aug 2005
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Jul 14, 2011
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00907738
Responsible party
Sponsor
First posted
May 25, 2009
Start date
Aug 2005
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jul 14, 2011
Last update
May 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion